BACKGROUND: The complement pathway and CD14 play essential roles in inflammation, but little is known about the relative roles of complement and CD14 in E. coli-induced tissue factor (TF) mRNA upregulation, expression by monocytes, and functional activity in human whole blood. METHODS: Whole E. coli bacteria were incubated for up to 4 h in human whole blood containing the anticoagulant lepirudin, which does not affect complement activation. TF mRNA levels were analyzed using reverse transcription, quantitative real-time PCR (RT-qPCR), and the expression of TF on the cell surface was analyzed using flow cytometry. Complement was selectively inhibited using the C3 convertase inhibitor compstatin or a C5a receptor antagonist (C5aRa), while CD14 was blocked by an anti-CD14 F(ab')2 monoclonal antibody. RESULTS: The E. coli-induced TF mRNA upregulation was reduced to virtually background levels by compstatin, whereas anti-CD14 had no effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced E. coli-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 efficiently reduced the expression of the E. coli-induced cytokines IL-1beta, IL-6, IL-8, and platelet-derived growth factor bb. CONCLUSION: Our results indicate that E. coli-induced TF mRNA upregulation is mainly dependent on complement activation, while CDI4 plays a modest role in monocyte TF expression and the plasma TF activity in human whole blood.
BACKGROUND: The complement pathway and CD14 play essential roles in inflammation, but little is known about the relative roles of complement and CD14 in E. coli-induced tissue factor (TF) mRNA upregulation, expression by monocytes, and functional activity in human whole blood. METHODS: Whole E. coli bacteria were incubated for up to 4 h in human whole blood containing the anticoagulant lepirudin, which does not affect complement activation. TF mRNA levels were analyzed using reverse transcription, quantitative real-time PCR (RT-qPCR), and the expression of TF on the cell surface was analyzed using flow cytometry. Complement was selectively inhibited using the C3 convertase inhibitor compstatin or a C5a receptor antagonist (C5aRa), while CD14 was blocked by an anti-CD14 F(ab')2 monoclonal antibody. RESULTS: The E. coli-induced TF mRNA upregulation was reduced to virtually background levels by compstatin, whereas anti-CD14 had no effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced E. coli-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 efficiently reduced the expression of the E. coli-induced cytokines IL-1beta, IL-6, IL-8, and platelet-derived growth factor bb. CONCLUSION: Our results indicate that E. coli-induced TF mRNA upregulation is mainly dependent on complement activation, while CDI4 plays a modest role in monocyte TF expression and the plasma TF activity in human whole blood.
Authors: Anub M Thomas; Alexandra Gerogianni; Martin B McAdam; Yngvar Fløisand; Corinna Lau; Terje Espevik; Per H Nilsson; Tom Eirik Mollnes; Andreas Barratt-Due Journal: J Immunol Date: 2019-08-14 Impact factor: 5.422
Authors: Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris Journal: Eur J Clin Invest Date: 2015-03-09 Impact factor: 4.686
Authors: Corinna Lau; Kristin S Gunnarsen; Lene S Høydahl; Jan Terje Andersen; Gøril Berntzen; Anne Pharo; Julie K Lindstad; Judith K Ludviksen; Ole-Lars Brekke; Andreas Barratt-Due; Erik Waage Nielsen; Christopher R Stokes; Terje Espevik; Inger Sandlie; Tom Eirik Mollnes Journal: J Immunol Date: 2013-09-23 Impact factor: 5.422
Authors: A Landsem; H Fure; D Christiansen; E W Nielsen; B Østerud; T E Mollnes; O L Brekke Journal: Clin Exp Immunol Date: 2015-08-02 Impact factor: 4.330
Authors: Maria I Fonseca; Shu-Hui Chu; Michael X Hernandez; Melody J Fang; Lila Modarresi; Pooja Selvan; Grant R MacGregor; Andrea J Tenner Journal: J Neuroinflammation Date: 2017-03-06 Impact factor: 8.322
Authors: A Landsem; H Fure; J Krey Ludviksen; D Christiansen; C Lau; M Mathisen; G Bergseth; S Nymo; K T Lappegård; T M Woodruff; T Espevik; T E Mollnes; O-L Brekke Journal: Clin Exp Immunol Date: 2018-12-19 Impact factor: 4.330